A New Paradigm in Drug Development - The mission of Bio-Path is to make its neutral lipid delivery the standard delivery technology for antisense therapeutics in the pharmaceutical industry.
Liposomal Grb-2 Clinical Trial

Bio-Path completed six cohorts of the Phase I clinical trial evaluating Liposomal Grb-2 in blood cancers. The drug’s safety profile continues to be favorable with no treatment-related serious adverse events reported and data suggests possible anti-leukemia activity. A maximum tolerated dose has yet to be reached. The clinical trial is being conducted at the MD Anderson Cancer Center.

Patients are currently being enrolled into a safety segment of a Phase II program evaluating Liposomal Grb-2 in combination with Ara-C for AML.

Latest News

Feb 1, 2016Bio-Path Holdings to Present at the 18th Annual BIO CEO & Investor Conference

Jan 26, 2016Bio-Path Hopes to Blaze Profitable Path With Antisense Drugs

Jan 6, 2016Bio-Path Holdings to Present at Biotech Showcase™ 2016

Dec 8, 2015
Bio-Path Holdings’ Data from Phase I and Safety Segment of Phase II Clinical Trials in Blood Cancers Presented at 57th American Society of Hematology (ASH) Annual Meeting

Two of the three evaluable patients achieved complete remission in safety segment of the Phase II combination therapy trial of BP1001 (Liposomal Grb2 antisense)